Thalidomide represents a promising immunomodulatory drug that targets both leukemia cells and the tumor microenvironment. We treated patients with chronic lymphocytic leukemia (CLL) with a combined thalidomide/fludarabine regimen and monitored cellular and molecular changes induced by thalidomide in vivo before fludarabine treatment. Thalidomide was given daily (100 mg p.o. per day) and fludarabine was administered on days 7-11 (25 mg/m 2 i.v. per day) within each 4-week cycle (maximum of 6 cycles). Twenty patients received thalidomide/fludarabine as first-line therapy and 20 patients were previously treated. Unmutated IgVH mutation status was found in 36 cases and 13 had high-risk cytogenetic aberrations (del17p, del11q). The overall response rate was 80 and 25% for untreated and previously treated patients, respectively. Although thalidomide reduced the number of CLL cells, the number of CD3 lymphocytes showed no significant change, but the number of CD4 þ CD25 hi FOXP3 þ regulatory T cells (Tregs) was significantly decreased. Gene expression profiling revealed a thalidomide-induced signature containing both targets known to have a function in immunomodulatory drug action as well as novel candidate genes. Combined thalidomide/fludarabine therapy demonstrated efficacy in high-risk patients with CLL. Furthermore, our study provides novel biological insights into thalidomide effect, which might act by enhancing apoptosis of CLL cells and reducing Tregs, thereby enabling T-cell-dependent antitumor effect.
Introduction
The clinical course of B-cell chronic lymphocytic leukemia (CLL) is highly variable. Although some patients will never require treatment, others suffer from an aggressively progressing leukemia that might result in death within several months. 1 Today, the characterization of several unfavorable molecular markers such as cytogenetic aberrations (deletion of 17p13 or 11q22-q23), unmutated IgVH mutation status, as well as elevated expression of the zeta-associated protein 70 (ZAP-70) proved to be valuable tools for risk stratification in CLL. Patients bearing these negative prognostic factors are characterized by poorer response to therapy and shorter treatment-free intervals. [2] [3] [4] [5] Recently, several novel mechanisms of tumor progression were characterized in CLL, stressing an important function of tumor microenvironment. Direct cell-cell interactions as well as soluble factors might support tumor growth. [6] [7] [8] [9] Prosurvival signals might be supported by the tumor necrosis factor (TNF) or some distinctive members of TNF family such as BAFF and APRIL as well as angiogenic factors VEGF. [6] [7] [8] By targeting not only leukemic cells but also the tumor microenvironment and by inhibiting angiogenesis, CLL might be more effectively treated.
Thalidomide and its analogue lenalidomide have been shown to be promising immunomodulatory compounds to achieve this goal. 10 Thus, thalidomide-based treatment might represent a novel therapeutic strategy for patients with CLL, and it has been suggested that the addition of fludarabine might enhance its antileukemic effect. 11 Furthermore, in CLL higher proportions of CD4 þ CD25 hi FOXP3 þ regulatory T cells (Tregs) have been described. 12 Although Tregs are potent to inhibit immune response in CLL including T-cell responses against tumor antigens, their increased percentages were normalized after effective treatment with fludarabine. 13 In the current study, we evaluated effects of thalidomide and the combination of thalidomide and fludarabine in two cohorts of patients with CLL, in patients with or without prior therapy. We assessed the influence of thalidomide on different T-cell subsets, especially those reported to modulate immune response because these might provide novel insights into mechanisms of thalidomide action. Finally, to better understand the molecular basis of clinical response to thalidomide, we applied gene expression profiling (GEP) to identify novel genes associated with response to thalidomide in patients with CLL.
Materials and methods

Patients
A total of 40 patients with CLL (median age 61.5, range 45-79 years) were enrolled in the study. Between 2005 and 2007, 20 untreated patients with CLL (arm A) and 20 patients (arm B), who relapsed after 2-6 previous therapy lines (median ¼ 3) with a median interval to prior therapy of 10 months, were treated at the Department of Hematooncology, Medical University of Lublin, Poland. All patients included in this trial met the criteria for progressive disease and need for therapy.
14 All previously treated patients had received fludarabine/cyclophosphamide and four of them were fludarabine refractory. The study was approved by the local ethics committee. Informed consent was obtained from all patients. Clinical characteristics are shown in Table 1 .
Study protocol
Patients received thalidomide (100 mg p.o. per day) starting at day 0. Fludarabine was added for 5 consecutive days every 28 days (25 mg/m 2 i.v. per day) starting at day 7 for up to 6 cycles. Patient received 100 mg acetylsalicylic acid for thrombosis prophylaxis. Clinical response was evaluated after 3 and 6 cycles of thalidomide/fludarabine using IWCLL response criteria.
14 Toxicity was assessed according to NCI Common Toxicity Criteria (CTC).
Cell isolation and RNA preparation
Peripheral blood mononuclear cells were isolated by Ficoll density and stored in liquid nitrogen for flow cytometric analysis. Molecular genetic characterization (detection of genomic aberrations by fluorescence in situ hybridization and determination of the IgVH mutational status by sequencing) was performed as previously described.
3,15
Evaluation of T-cell subpopulations
To define T-cell subsets, we performed the staining of the surface antigens CD3, CD4, CD8, TCRgd, CD25, CD28, CD62L and GITR (glucocorticoid-induced TNF receptor; BD Biosciences, Mannheim, Germany) after incubation of 1 Â 10 6 cells with antibodies according to the manufacturer's protocols. To characterize regulatory T cells (Tregs), we permeabilized cells stained with CD3, CD4 and CD25, then stained them with anti-FOXP3 (eBiosciences, San Diego, CA, USA) and analyzed as previously described. 16 
TNF ELISA and TNF receptor expression analysis
Serum was separated and stored at À80 1C. The TNF level in the serum was determined by human TNF-alpha Quantikine HS enzyme-linked immunosorbent assay (ELISA; R&D Systems, Minneapolis, MN, USA) according to manufacturer's protocols. Expression of TNF-R1 and TNF-R2 was performed by flow cytometric analysis as described earlier. 17 
Gene expression profiling
To evaluate the in vivo influence of thalidomide on the transcriptome in CLL, we performed paired GEP in 20 cases at treatment start at day 0 and before fludarabine treatment at day 7 (10 arm-A and 10 arm-B cases), using HumanGenome U133 Plus2.0 Arrays (Affymetrix, Santa Clara, CA, USA) according to the manufacturer's recommendations (RNA was isolated from peripheral blood samples enriched for leukemic cells by Ficolldensity gradient centrifugation, percentage of leukemic cells 490%). Fluorescence ratios were normalized by applying the RMA algorithm using the BRB Array Tools software (available at http://linus.nci.nih.gov/BRB-ArrayTools.html). The complete microarray data are available at Gene Expression Omnibus (accession no. GSE15913).
Statistical analysis
All results are presented as median values±range. The MannWhitney U-test was used to evaluate the differences between the subgroups of patients. To identify genes whose expression changed significantly during treatment with thalidomide, we applied 'class comparison analyses' and 'gene set enrichment analyses' using BRB Array Tools Version 3.3.0 Beta_3 developed by Dr Richard Simon and Amy Peng Lam and using R, version 2.2.1 (http://www.r-project.org) as previously described. 18, 19 All tests reported were two sided with an effect being considered significant if the P-value was 0.05 or less.
Results
Toxicity
A flare reaction with tenderness of involved lymph nodes sites and rash was observed during the first cycle in 10 patients (7 cases receiving first-line therapy and 3 pretreated patients). Sudden enlargement and tenderness of lymph nodes and spleen (in some cases) as well as low-grade fever and rash were the leading symptoms (flare reaction was treated with nonsteroidal anti-inflammatory drugs). Moderate side effects including constipation (95%) and fatigue were noted in all patients. Infectious complications were noted in 18 patients (45%) with 4 being serious (CTC 3-41). Allergic skin reaction to thalidomide was observed in one patient and deep venous thrombosis in another patient. Four patients developed autoimmune hemolytic anemia (AIHA) with positive Coombs test (CTC 3-41) during the treatment course. Treatment-related toxicity results are summarized in Supplementary Table 1 .
Clinical response
The overall response rate (ORR) was 52.5% (21 of 40 patients). Higher ORR (80%) was observed in patients receiving thalidomide/fludarabine as first-line therapy (arm A) when compared to previously treated patients (arm B, ORR ¼ 25%; Table 2 ). In arm A, 16 patients completed all 6 cycles of therapy. There was one early death due to infectious complications. Three patients discontinued the study after 3 cycles because of treatmentrelated neuropathy (CTC 431; Supplementary Table 1 ). In arm B severe toxicity (AIHA and infectious complications) resulted in three deaths. Among 12 patients not responding after 3 months Table 2b .
Cellular and molecular responses
Cellular and molecular responses were evaluated on days 0 (before initiation of therapy), 7 (thalidomide monotherapy) and 12 (thalidomide/fludarabine therapy). We observed a reduction of the total WBC after thalidomide monotherapy (from median 74.8 G/l (day 0) to 59.15 G/l (day 7), P ¼ 0.14) and further reduction to a median of 26.1 G/l after addition of fludarabine ((day 12) P ¼ 0.0002, Figure 1a ). Similarly, thalidomide induced a reduction of total lymphocyte counts from a median of 69 G/l at day 0 to 43.4 G/l at day 7 (P ¼ 0.067). Following the administration of fludarabine, lymphocyte counts dropped to a median value of 17.45 G/l ((day 12) Po0.0001, Figure 1b) . Overall, responders to therapy tended to have a higher WBC reduction after thalidomide monotherapy on day 7 than nonresponders (median reduction 19.45 vs 2.2 G/l, P ¼ 0.097). In detail, in arm A responders showed a WBC reduction of 10.2 G/l compared to a median increase of 11.3 G/l in nonresponders (P ¼ 0.036), and in arm B responders also tended to have a greater reduction of WBC numbers (24 vs 11.75 G/l in nonresponders, P ¼ 0.41).
Changes in lymphocyte subpopulations
Thalidomide therapy decreased the number of CLL cells (CD5 þ CD19 þ ) from an initial median of 51.75 G/l (day 0) to 31.7 G/l (day 7) (P ¼ 0.16, Figure 1c ). Subsequent therapy with thalidomide/fludarabine further reduced the number of CLL cells (median 16.8 G/l (day 12), P ¼ 0.007, Figure 1c ). The number of CD3 þ lymphocytes showed no significant change after thalidomide monotherapy (2599 cells per ml on day 0 and 2166 cells per ml on day 7), but thalidomide/fludarabine decreased CD3 þ cells to a median of 853 cells per ml on day 12 (P ¼ 0.01, Figure 1d ). Thalidomide induced no effect on CD4 þ as well as CD8 þ T-cell subpopulations (Figure 1e ), but both CD4 þ and CD8 þ T-cell subsets were significantly reduced after therapy with thalidomide/ fludarabine (P ¼ 0.008 and P ¼ 0.009, respectively).
There was a decrease in the number of CD4 þ CD25 hi FOXP3 þ Tregs after thalidomide therapy (182 cells per ml on day 0 and 114 cells per ml on day 7; P ¼ 0.05). Tregs were further reduced after thalidomide/fludarabine therapy (43.9 cells per ml on day 12; P ¼ 0.001, Figure 1f ). Because the absolute numbers of lymphocytes differed significantly, we calculated Tregs fold changes (values o0 ¼ reduction, values 40 ¼ increase of Tregs). Although thalidomide induced a significant reduction of Tregs (median fold change: À2.01, range: À19.39 to 2.13), the changes differed in responders vs nonresponders. Clinical responders showed a greater Tregs reduction (median fold change: À2.09, range: À5.15 to 2.13) than patients who did not respond (median fold change: À1.35, range: À19.39 to 2.02, P ¼ 0.042, Figure 2e ).
Thalidomide monotherapy did not reduce the number of other T-cell subpopulations reported to possess regulatory properties such as CD8 Figure 1) . In contrast, thalidomide/ fludarabine therapy decreased the number of CD8 þ CD28 Supplementary Figure 1 ).
Thalidomide effects on TNF-R1 and TNF-R2 expression and TNF serum levels
Thalidomide was reported to effectively reduce TNF levels in patients with multiple myeloma (MM), who responded to therapy. We therefore evaluated the influence of thalidomide on TNF serum levels and correlated response to thalidomide monotherapy with TNF receptor expression (patients with WBC reduction on day 7 were defined as thalidomide responders). We observed no significant changes in the serum levels of TNF on days 7 and 12. No correlation was observed between TNF serum levels and TNF-R1 or TNF-R2 expression. However, the expression of TNF-R1 was significantly higher in thalidomide nonresponders (median: 19.98 vs 9.7, P ¼ 0.03, Figure 2a ), Thalidomide responders ¼ reduced WBC after thalidomide monotherapy.
Molecular and immunological effects of THAL in CLL K Giannopoulos et al who also tended to present with higher TNF-R2 levels (median: 51.6 vs 33.1, P ¼ 0.17, Figure 2b ). Furthermore, TNF serum levels at day 0 were lower in thalidomide responders compared to nonresponders (median: 0.75 vs 3.84 pg/ml, P ¼ 0.09, Figure 2c ).
Thalidomide-induced gene expression changes
A paired supervised analysis based on day 0 and 7 GEP data revealed a thalidomide-induced signature comprising 123 differentially expressed genes (paired t-test with random variance model, Po0.001; Figure 3 and Supplementary Table 2) . Upon thalidomide monotherapy, we observed an upregulation of genes known to be involved in mediating thalidomide response, such as FAS and CDKN1A, as well as novel candidate genes, such as STAT1 and IKZF1. In accordance, a gene set enrichment analysis investigating 271 BioCarta pathways showed 22 significantly deregulated pathways (random variance model, Po0.005) including pathways involved in apoptosis, angiogenesis, cytokine, platelet-derived growth factor (PDGF) and p38 MAPK signaling. We also observed an enrichment of genes belonging to the 'function of BRCA1, BRCA2 and ATR in cancer susceptibility' pathway, which includes TP53 and ATM (Table 3) . 
Figure 1 Changes in numbers of white blood cells (WBCs) (a) and lymphocytes (b), CLL cells (c), CD3
þ lymphocytes (f) before (day 0) and after thalidomide (day 7) and fludarabine (day 12) therapy. WBC counts (a) as well as lymphocyte counts (b) were assessed using an automated hematological analyzer. Changes in the number of chronic lymphocytic leukemia (CLL) cells, characterized as
þ (e) and CD4 þ CD25 hi FOXP3 þ T lymphocytes, were assessed by flow cytometry from peripheral blood samples frozen on days 0, 7 and 12.
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Comparison of our in vivo-derived thalidomide signature with data stored in Connectivity Map, 20 a collection of genome-wide transcriptional expression data from in vitro cultured human cells treated with bioactive small molecules, revealed a significant correlation of our findings with thalidomide-induced changes in MCF7 breast cancer cells (rank 18, score 0.578). This provides further evidence that our in vivo gene expression changes reflect thalidomide-induced effects.
Gene expression patterns associated with response to therapy
Because not all patients responded to thalidomide/fludarabine therapy, we were interested to analyze whether we could determine gene expression differences in responders as compared to nonresponders after thalidomide monotherapy at day 7. Responders showed lower expression of pro-survival cytokines such as IL-8 and lower levels of TGFB1, whereas genes involved in apoptosis, for example CASP1, were more highly expressed than in nonresponders (Supplementary Table 3 ). On the other hand, nonresponders showed higher ZAP-70 expression as determined by microarray analysis and higher expression levels of anti-apoptotic genes, for example TRAF1, and gene involved in angiogenesis, for example ECGF1 (Supplementary Tables 3  and 4) .
Paired analysis evaluating intra-individual expression changes in thalidomide responders showed also an enrichment of genes belonging to FAS, EGF, PDGF and apoptosis signaling as well as p53 and ATM signaling in accordance to the analyses of all samples (Supplementary Table 5 ). However, only thalidomide responders showed also a correlation with the CD40L signaling pathway.
We were also able to define a day 0-derived signature associated with thalidomide response at day 7 as well as overall response (Supplementary Tables 6 and 7 , respectively). While pretreatment samples responding to thalidomide differed from nonresponders with regard to the expression of, for example, JUN and CASP9 associated with, for example, insulin and RAS signaling pathways, respectively (Supplementary Table 8 ), samples of patients with an overall response were characterized by lower IL8 levels with the signature being enriched for the pathways 'cytokines and inflammatory response', 'integrin signaling and cytokines' as well as 'inflammatory response' (Supplementary Table 9 ).
Discussion
After almost five decades thalidomide has been rediscovered as a potent antitumor drug. Although thalidomide has proved to be effective for patients with MM, 21 recently first promising results were also reported in treatment-naive patients with CLL with five complete and four partial remissions in nine patients completing six courses of thalidomide/fludarabine therapy. 11 Furthermore, in this study thalidomide was reported to reduce the WBC after 1 week of treatment.
11
In the current study, we investigated a larger cohort composed mostly of IgVH unmutated cases with CLL. We could demonstrate that thalidomide/fludarabine represents a feasible therapeutic option for patients with CLL with encouraging data especially for treatment-naive cases. Moreover, in patients with high-risk cytogenetic aberrations (deletion of 17p13 or 11q22-q23), ORR was 38% with almost 70% of cases showing a cell reduction after thalidomide monotherapy. These results are in accordance with a recent study evaluating the use of lenalidomide in patients with CLL, which showed a response to treatment with immunomodulatory drugs (IMiDs) in high-risk patients with CLL. 22 Interestingly, in our study two out of four (50%) 17p-deleted refractory cases with CLL responded to thalidomide (reduction of WBC on day 7) as well as thalidomide/fludarabine therapy, suggesting that IMiDs may be effective in 17p-deleted patients with CLL. In addition, thalidomide/fludarabine therapy might also be considered in refractory patients with CLL.
Thalidomide induces pluripotent effects, but the mechanism of action is still not well understood. 23 Thalidomide inhibits various cytokines, for example IL-6, TNF and VEGF, that have important functions in angiogenesis. In patients with MM responding to thalidomide decreased VEGF, bFGF, IL-6 and TNF levels were noted. 24 In heavily pretreated patients with CLL, failure of treatment with thalidomide, fludarabine and cyclophosphamide was associated with an increase of TNF serum level. 25 In the current study, we observed a tendency toward an increase of TNF serum levels in thalidomide nonresponders. Moreover, these cases presented with higher levels of TNF-R1, TNF-R2 as well as TNF expression at diagnosis. However, in the current study as well as in a previous report some cases with CLL responded to thalidomide irrespective of TNF levels. 26 Thus, TNF seems to be involved in thalidomide action, but might not represent the main target in CLL.
Thalidomide therapy resulted in a specific reduction of
þ Tregs, which was higher in responders. By targeting Tregs, thalidomide could enhance the immune response to CLL cells by enabling T-cell-dependent tumor rejection. As no influence was noted on CD3 þ lymphocyte subpopulations as well as other T-cell subsets reported to possess regulatory properties (
, the reduction of Tregs seems to be restricted to the CD4 þ CD25 hi FOXP3 þ T-cell subset. Therefore, thalidomide action might be immunologically superior to fludarabine as there is no effect on CD3 þ , CD4 þ and CD8 þ T cells, thereby allowing them to fulfill their immunological function.
For an improved understanding of in vivo effects of thalidomide, we profiled gene expression in a subset of patients. Screening the Connectivity Map database showed that thalidomide-induced in vivo expression changes were highly correlated with in vitro findings. This provides further evidence that the molecular and clinical treatment effects observed in our study are thalidomide specific. In accordance, gene expression changes included candidates known to be affected by IMiD treatment of B-cell malignancies, such as an upregulation of FAS with concomitant downregulation of TGFB1 and PDGFC in IMiD responders. 23 However, we also identified novel thalidomide target genes, such as STAT1, which is downstream of interferon-g, EGF and PDGF, and has a central function in B-lymphocyte growth and function. 27 Furthermore, thalidomide induced an upregulation of IKZF1 (coding for Ikaros), a gene commonly targeted by genetic lesions in lymphoid neoplasms that result in the loss of Ikaros function, an important event in leukemogenesis. 28, 29 For thalidomide nonresponders, microarray analyses showed increased ZAP-70 expression, a gene previously identified by GEP analysis to be associated with poor outcome in CLL. 30 In addition, higher expression levels of genes involved in angiogenesis (for example, ECGF1) and anti-apoptotic genes (such as TRAF1), which encodes an anti-apoptotic protein implicated in lymphoid malignancies, 31 characterized DOPEY1 DOPEY1  DPY19L2P2 DPY19L2P2   TTC28 TTC28  MGC3032 MGC3032  FMO5 FMO5  LOC644285 LOC644285   TTC28 TTC28  NAV1 NAV1  TK2 TK2  GK GK  CPD CPD  CALM1 CALM1   PRDM15 PRDM15  MGC33894 MGC33894  SLC14A1 SLC14A1  MYBL1 MYBL1  LOC344405 LOC344405  IL4R IL4R  NBR2 NBR2   ITPKB ITPKB  CDKN1C CDKN1C  CDKN1C CDKN1C   TRPM4 TRPM4  APOL6 APOL6  LILRB4 LILRB4  ZWINT ZWINT  IFIT3 IFIT3   FAS FAS  FBXO6 FBXO6  GBP4 GBP4   FGFR1 FGFR1  RCAN1 RCAN1  KIAA0748 KIAA0748  CD59 CD59  IL17RB IL17RB  INPP5F INPP5F  DAZL DAZL  BSPRY BSPRY  IL4I1 IL4I1  ANGPTL6 ANGPTL6  TTLL9 TTLL9  ALPK1 ALPK1  LAG3 LAG3  SFTPB SFTPB  SFTPB SFTPB  C1orf217 C1orf217  ARSD ARSD  CDR2 CDR2  KPTN KPTN   CFLAR CFLAR  C19orf36 C19orf36  C1orf95 C1orf95  BCAR3 BCAR3   LOC149478 LOC149478  MGC33556 MGC33556  MGC33556 MGC33556  LOC158402 LOC158402  STAT1 STAT1  BSPRY BSPRY  GRN GRN  ZNF692 ZNF692  SUSD1 SUSD1  CDKN1A CDKN1A  GRN GRN  STAT1 STAT1  ATP2B4 ATP2B4  C17orf48 C17orf48  CRKRS CRKRS  C17orf49 C17orf49  ENTPD1 ENTPD1  CFLAR CFLAR  PARP9 PARP9  RAB20 RAB20  ENTPD1 ENTPD1  RHOC RHOC  ENTPD1 ENTPD1   IL17RB IL17RB  GLDN GLDN  MEST MEST  WSB2 WSB2  CD59 CD59   KSR2 KSR2   ATOX1 ATOX1  OAS3 OAS3  ZBTB32 ZBTB32  ITGAX ITGAX  STAT1 STAT1  IFI44 IFI44  IFI44L IFI44L  GALM GALM  ANKRD16 ANKRD16  WDR91 WDR91  PIP5K1B PIP5K1B  PLEKHA7 PLEKHA7   SPATS2 SPATS2  IKZF1 IKZF1  CPM CPM  CPM CPM  DKFZP761N09121 DKFZP761N09121  TPM2 TPM2  TncRNA TncRNA  GLYATL2 GLYATL2  ALPK1 ALPK1   IL13RA1 IL13RA1   CLL#15 CLL#15  CLL#19 CLL#19  CLL#2 CLL#2  CLL#20 CLL#20  CLL#11 CLL#11  CLL#13 CLL#13  CLL#9 CLL#9  CLL#4 CLL#4  CLL#5 CLL#5  CLL#18 CLL#18  CLL#8 CLL#8  CLL#10 CLL#10  CLL#6 CLL#6  CLL#3 CLL#3  CLL#1 CLL#1  CLL#7 CLL#7  CLL#12 CLL#12  CLL#17 CLL#17  CLL#16 CLL#16  CLL#14 thalidomide nonresponse. On the other hand, thalidomide responders showed lower JUN and CASP9 expression levels associated with deregulated insulin and RAS signaling pathways, respectively. 32 Furthermore, treatment responders were characterized by lower IL8 levels. In CLL being induced by nuclear factor-kB activation, IL8 may function as an autocrine growth and apoptosis resistance factor promoting cell survival in these cases. 33, 34 In summary, our study provides novel biological insights into the molecular effects of thalidomide, which might act by enhancing apoptosis of CLL cells and by reducing Tregs, thereby enabling T-cell-dependent tumor rejection. Our data also suggest the existence of a signature predictive of thalidomide response in CLL, which provides novel insights of potential pathogenic relevance. Furthermore, we could demonstrate that thalidomide/fludarabine therapy is effective in patients with CLL. Especially in high-risk IgVH unmutated cases with unfavorable cytogenetic aberrations, thalidomide/fludarabine therapy might warrant further study. 
